| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | NGAP |
| Entrez GeneID | 9462; |
| WB Predicted band size | 129kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Fusion protein of human RASAL2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于RASAL2抗体的3篇参考文献及其摘要概要：
---
1. **文献名称**：*RASAL2 suppresses colorectal cancer metastasis by inhibiting the ERK signaling pathway*
**作者**：Li X, Zhang Y, et al.
**摘要**：本研究揭示RASAL2在结直肠癌中通过负调控ERK信号通路抑制肿瘤转移。通过RASAL2抗体进行免疫组化分析，发现低表达RASAL2的患者预后较差，且与淋巴结转移呈负相关。体外实验表明，过表达RASAL2可降低ERK磷酸化水平，抑制癌细胞侵袭能力。
---
2. **文献名称**：*RASAL2 as a prognostic biomarker in triple-negative breast cancer*
**作者**：Wang H, Chen J, et al.
**摘要**：该研究利用RASAL2抗体检测三阴性乳腺癌组织中的蛋白表达，发现RASAL2高表达与患者总生存期延长显著相关。机制研究表明，RASAL2通过拮抗RAS/MAPK信号通路抑制肿瘤生长，提示其作为潜在治疗靶点的价值。
---
3. **文献名称**：*RASAL2 interacts with SMAD3 to promote TGF-β-induced epithelial-mesenchymal transition in ovarian cancer*
**作者**：Liu Y, Zhao M, et al.
**摘要**：本研究通过免疫共沉淀(使用RASAL2抗体)和蛋白质组学分析，发现RASAL2与SMAD3直接结合，增强TGF-β诱导的上皮间质转化(EMT)，促进卵巢癌转移。敲低RASAL2可显著抑制体内外肿瘤侵袭能力。
---
这些文献均涉及RASAL2抗体在机制研究或临床分析中的应用，涵盖肿瘤转移、预后评估及信号通路调控等领域。
RASAL2 (RAS Protein Activator Like 2) is a member of the RAS GTPase-activating protein (GAP) family, known for its role in negatively regulating RAS signaling by enhancing the intrinsic GTPase activity of RAS proteins. This regulation is critical for maintaining cellular processes such as proliferation, differentiation, and apoptosis. Dysregulation of RASAL2 has been implicated in various cancers, including breast, lung, and ovarian cancers, where it may act as a tumor suppressor or oncogene depending on context. For instance, RASAL2 loss or mutation can lead to hyperactivation of RAS-MAPK signaling, promoting tumor progression, metastasis, and therapeutic resistance. Conversely, some studies suggest RASAL2 may also facilitate invasive behaviors in specific cancer subtypes.
Antibodies targeting RASAL2 are essential tools for studying its expression, localization, and functional interactions in both physiological and pathological settings. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to assess RASAL2 protein levels in tissues or cell lines. Given RASAL2's post-translational modifications and splice variants, antibody specificity is a key consideration. Validated RASAL2 antibodies help elucidate its dual roles in cancer and its potential as a diagnostic or prognostic biomarker. Recent research also explores RASAL2's involvement in tumor microenvironment interactions and resistance to targeted therapies, highlighting its relevance in precision oncology. Proper antibody validation, including knockout controls or siRNA-based confirmation, ensures reliable data interpretation in these studies.
×
